From regulatory strategy to quality systems and product commercialization, our experts share practical guidance to help medical device, pharmaceutical, and biotech companies accelerate compliance and reduce risk.
Effective February 2, 2026, the QMSR amended 21 CFR Part 820 by incorporating ISO 13485:2016 by reference, bringing FDA's medical device quality management requirements into closer alignment with internationally recognized practices. For medical device manufacturers, however, the significance of this change extends beyond updating procedures or aligning documentation with a revised regulatory framework.
At OneGlobal Trinity M Consulting, we help medical device, pharmaceutical, and biotechnology organizations bridge the gap between strategy and execution.
Our approach is centered on practical, cross-functional support that helps organizations understand what needs to be accomplished, establish a realistic path forward, manage risks and dependencies, and keep critical programs moving.
At OneGlobal Trinity M Consulting, we partner with pharmaceutical, biotech, and medical device companies to navigate the unique regulatory, clinical, and strategic pathways required for successful orphan drug development and approval.